1-2 of 2
Michael R. Silvestrone
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Minimal Residual Disease (MRD)-Adapted Duration of Front-Line Venetoclax and Obinutuzumab Treatment for Fit Patients with Chronic Lymphocytic Leukemia (CLL)

Lindsey Roeker, Anthony R. Mato, Andrew D. Zelenetz, Jae H. Park, Mark Blaine Geyer, Andriy Derkach, David Nemirovsky, Prioty Islam, Lorenzo Falchi, Maria Lia Palomba, Anita Kumar, Gilles Salles, Jennifer Kimberly Lue, Aaron D. Goldberg, Deborah M. Stephens, Victoria Duffy, Gail Panton, Dianna Tyznar, Colleen Dorsey, Dhara Soni, Claire Hutzler, Lauren Nogan, Alexandra Allen, Tenzin Nyima, Thu Quynh Nguyen, Monica Shah, Tamotha R Cook, Jennifer Abillar-Wright, Jamila Brutus, Carissa Laudati, Bejal Kikani, Catherine C Coombs, Michael R. Silvestrone, Christopher E. Jensen, Bita Fakhri, Meghan C. Thompson
Journal: Blood
Blood (2024) 144 (Supplement 1): 1010.
https://doi.org/10.1182/blood-2024-203807
Published: 2024
Journal Articles

Chemotherapy-Sparing Induction Followed By Consolidation and Maintenance with Blinatumomab and Concurrent Oral Tyrosine Kinase Inhibitor Therapy for Newly-Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Primary Endpoint Results from the Blissphall Study

Mark Blaine Geyer, John Mascarenhas, Marissa Smith, Shakira Pascual, Anmol Shah, Michael R. Silvestrone, Tina Czaplinska, Kathryn Johnson, Meghan C. Thompson, Jae H. Park
Journal: Blood
Blood (2023) 142 (Supplement 1): 1510.
https://doi.org/10.1182/blood-2023-173551
Published: 2023